GLP1R and hematopoietic and lymphoid system neoplasm: As might be expected, GLP-1 receptor agonist use has been most robustly associated with reduced risk of various obesity-related cancers, including colorectal and pancreatic, with recent analyses demonstrating that use is associated with variously reduced risk of 10 of 13 obesity-associated cancers.8, 9, 10 Here, we sought to answer the question of whether GLP-1 receptor agonist use also modifies risk of hematologic neoplasms.